- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01134315
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
May 17, 2013 updated by: AbbVie (prior sponsor, Abbott)
A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
Investigators were free to determine the appropriate therapy for each participant based on clinical judgment.
Decisions to prescribe paricalcitol or calcitriol were made independently prior to enrollment of participants in this observational study.
Study Type
Observational
Enrollment (Actual)
61
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35255
- Site Reference ID/Investigator# 37082
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Site Reference ID/Investigator# 26762
-
Orlando, Florida, United States, 32801
- Site Reference ID/Investigator# 28529
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Site Reference ID/Investigator# 26748
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70118
- Site Reference ID/Investigator# 37582
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Site Reference ID/Investigator# 39973
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Site Reference ID/Investigator# 26769
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Site Reference ID/Investigator# 26768
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Site Reference ID/Investigator# 26747
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Site Reference ID/Investigator# 26749
-
Cincinnati, Ohio, United States, 45229
- Site Reference ID/Investigator# 26751
-
Columbus, Ohio, United States, 43205
- Site Reference ID/Investigator# 26765
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Site Reference ID/Investigator# 28528
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Site Reference ID/Investigator# 26763
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Site Reference ID/Investigator# 28526
-
-
Washington
-
Seattle, Washington, United States, 98105
- Site Reference ID/Investigator# 26758
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Site Reference ID/Investigator# 40382
-
Wauwatosa, Wisconsin, United States, 53226
- Site Reference ID/Investigator# 26759
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This was a multicenter, United States only study of pediatric (0 to 16 years) males and females receiving peritoneal dialysis, treated in a routine clinical setting.
Patients were recruited from private nephrology practices or hospitals.
Description
Inclusion Criteria:
- Male or female between 0 to 16 years of age (inclusive), on peritoneal dialysis for at least 30 days.
- The patient has a history of secondary hyperparathyroidism as defined by having initiated a vitamin D receptor activator to treat an elevated parathyroid hormone level.
- The patient is attending a site associated with North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Dialysis Registry.
- Patient and the patient's parent or legal guardian must voluntarily sign and date an informed consent and/or assent, approved by the local Independent Ethics Committee/Institutional Review Board, prior to the initiation of any screening or study-specific procedures.
- Patient has received paricalcitol or calcitriol for a minimum of 10 days.
Exclusion Criteria:
- Patient is scheduled for a kidney transplant within 3 months.
- Patient is expected to stop peritoneal dialysis within 3 months.
- Patient is expected to transfer to hemodialysis within 3 months.
- Patient is planning to be enrolled in an investigational study where the drug and/or dose are unknown to the investigator within the first 3 months from the date of patient enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Paricalcitol
Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT).
Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
|
Other Names:
|
Calcitriol
Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT).
Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With at Least One Incidence of Hypercalcemia
Time Frame: Monitored from time of informed consent through end of study + 30 days (total of 745 days).
|
Hypercalcemia was defined as calcium >10.2 mg/dL.
Percentage of participants with hypercalcemia is presented for the overall population, the subgroup of participants in the study for less than 3 months, and those in the study for greater than or equal to 3 months.
|
Monitored from time of informed consent through end of study + 30 days (total of 745 days).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs
Time Frame: Monitored from time of informed consent through end of study + 30 days (total of 745 days).
|
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment; any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered causally related to the use of the product (either paricalcitol or calcitriol); can result from use of the drug as stipulated in the labeling, as well as from accidental or intentional overdose, drug abuse, or drug withdrawal; any worsening of a pre-existing condition or illness.
Severity was categorized as mild, moderate, or severe.
SAE: AE that results in the death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome; is a spontaneous or elective abortion.
For more details, please see the AE section of this record.
|
Monitored from time of informed consent through end of study + 30 days (total of 745 days).
|
Mean Baseline (BL) and Change From Baseline in Potassium, Sodium, Chloride, Bicarbonate at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Mean Baseline (BL) and Change From Baseline in Calcium, Inorganic Phosphate (IP), Blood Urea Nitrogen (BUN), Creatinine at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Mean Baseline and Change From Baseline in 25-Hydroxy Vitamin D3 at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Mean Baseline and Change From Baseline in 1,25-Dihydroxy Vitamin D3 at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Mean Baseline and Change From Baseline in Parathyroid Hormone at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Mean Baseline and Change From Baseline in Albumin at Final Visit (FV)
Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Normal ranges for these chemistry measurements varied according to the age of the participant.
|
Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
May 28, 2010
First Submitted That Met QC Criteria
May 28, 2010
First Posted (Estimate)
June 2, 2010
Study Record Updates
Last Update Posted (Estimate)
August 13, 2013
Last Update Submitted That Met QC Criteria
May 17, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Endocrine System Diseases
- Renal Insufficiency
- Parathyroid Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperparathyroidism
- Kidney Failure, Chronic
- Hyperparathyroidism, Secondary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Micronutrients
- Membrane Transport Modulators
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vasoconstrictor Agents
- Calcium Channel Agonists
- Calcitriol
Other Study ID Numbers
- P12-053
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
University of KansasCompletedEnd-Stage Renal Disease
-
Eisai Co., Ltd.CompletedEnd-Stage Renal DiseaseJapan
Clinical Trials on Calcitriol
-
Rockefeller UniversityCompletedAdenocarcinoma | Colorectal Polyps | Colorectal AdenomaUnited States
-
Centro de Excelencia en Enfermedades de Cabeza...IPS universitariaNot yet recruitingGoiter | Hyperthyroidism | Thyroid Cancer | ThyroiditisColombia
-
ShireCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedProstate Cancer | Precancerous/Nonmalignant ConditionUnited States
-
Galderma R&DCompletedPlaque PsoriasisUnited States
-
Atlanta VA Medical CenterEmory UniversityWithdrawn
-
OHSU Knight Cancer InstituteCompletedProstate CancerUnited States
-
Atlanta VA Medical CenterEmory UniversityCompletedRheumatoid Arthritis | Crohn's DiseaseUnited States
-
National Center for Research Resources (NCRR)Boston UniversityCompleted
-
Galderma R&DCompletedPlaque PsoriasisUnited States, Spain, Germany, Italy, Belgium, Canada, Hungary